Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Neuroendocrine Tumors 2Neoplasms 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Neuroectodermal Tumors, Primitive 1Lung Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoid Tumor 1

Interventions

Sorafenib 10Magnetic Resonance Spectroscopy 10trametinib 8lenvatinib 8dabrafenib 7pembrolizumab 6Nivolumab 6Iodine-131 6Everolimus 6Sunitinib 5Paclitaxel 5vandetanib 4apatinib 4Thyrotropin Alfa 4Doxorubicin 4selpercatinib 3anlotinib 3Specimen Handling 3Radiotherapy 3Ipilimumab 3Iodine-124 3Fluorodeoxyglucose F18 3Cisplatin 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3tislelizumab 2tipifarnib 2surufatinib 2spartalizumab 2pazopanib 2omipalisib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Thyroid Neoplasms × fosbretabulin × Clear all
NCT00060242 2010-06-11

Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer

Case Comprehensive Cancer Center

Phase 2 Completed
26 enrolled
EndocrineHead & Neck

Head and Neck Neoplasms, Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡